|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Additional procode: hwc.Initial reporter is a synthes employee.The device was received, the investigation is in progress, no conclusion could be drawn at the time of filing this report.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.H10 additional narrative: h3, h6: part: 02.118.408-us, lot: 721p183, part manufacture date: 21 march 2022, manufacturing location: elmira, a review of the device history record revealed no complaint related anomalies.The device history record shows this lot of 2.7mm va-lcp lateral distal fibula plate/7 holes/right was processed through the normal manufacturing and inspection operations in elmira with no rework nor nonconformities noted.This lot met all dimensional, visual, and packaging criteria at the time of release from elmira with no issues documented during the manufacture that would contribute to this complaint condition.A review of the raw material device history record revealed this lot met all specifications with no nonconformance noted.This raw material lot met all dimensional and visual criteria at the time of manufacture with no issues documented during the manufacture that would contribute to this complaint condition.The product was returned to depuy synthes and sent to manufacturing site: jabil elmira for evaluation.The jabil elmira team conducted a visual inspection of the returned device.Visual analysis of the returned sample was performed on 2.7 va-lcp lateral dstl fib pl/7 h/rt.The returned device was received loose in a bag and laser etched part number 02.118.408 plate, batch 721p183.A visual inspection of the 2.7mm va-lcp lateral distal fibula plate/7 holes/right shows the plate appears to be in the same acceptable conforming condition cosmetically per inspection sheet and top-level drawing as it was when it shipped from the jabil elmira manufacturing facility.Per inspection sheet used for final inspection of the 02.118.408 plate, a 100% cosmetic inspection was performed at normal reading distance, understanding and using visual standards, on batch 721p183 prior to release of product to the warehouse.During the evaluation of the 02.118.408 plate involved in this complaint, the quality engineer determined the plate was in acceptable conforming condition.The available data does not support the complainant¿s description of the complaint condition, and there is no evidence to support the allegation made in the complaint.The complaint condition is unconfirmed or could not be confirmed based on the available data.A dimensional inspection was performed for the 2.7 va-lcp lateral dstl fib pl/7 h/rt and met specifications.As part of depuy synthes quality process, all devices are manufactured, inspected, and released to approved specifications.The overall complaint was not confirmed for the 2.7 va-lcp lateral dstl fib pl/7 h/rt.There is no indication that a design or manufacturing issue has caused the complaint condition and hence the root cause cannot be determined.Based on the investigation findings, it has been determined that no corrective and/or preventative action is proposed.Additional monitoring for any potential safety signals will be conducted through complaint trending and other post-market safety surveillance activities.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|